According to FutureWise analysis the market for her2- positive breast cancer in 2023 is US$ 10.86 billion, and is expected to reach US$ 12.45 billion by 2031 at a CAGR of 1.72%.
Breast cancer with HER2-positive status measures the presence of a protein called human epidermal growth factor receptor 2 (HER2). Cancer cells grow faster when this protein is present. Treatments that target HER2 specifically are very effective. As a result of these treatments, the prognosis for HER2-positive breast cancer is actually quite good. The use of certain standard chemotherapy drugs can also be effective in treating HER2-positive breast cancer, although these drugs do not specifically target HER2. HER2-positive breast cancer is when breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor) that helps them grow, divide, and repair themselves normally. There are times, however, when the HER2 gene malfunctions and you make too many of these receptors, causing your breast cells to grow and divide uncontrollably. About one in five breast cancers is HER2-positive. The most common malignancy among women in the USA is breast cancer, which is the second leading cause of cancer death in women. Based on gene expression profiling, breast cancer is a heterogeneous disease with at least five subtypes. As a result of HER2-targeted therapy, most notably trastuzumab, the natural history of HER2-positive breast cancer has dramatically improved.
HER2-positive breast cancer is diagnosed by immunohistochemistry (IHC), which identifies overexpression of the HER2 gene product, and fluorescence in situ hybridization (FISH), which identifies HER2 gene amplification. Tumors with indeterminate results by IHC (2+) should undergo reflex FISH testing, according to the College of American Pathology (CAP). FISH is used routinely by some institutions because it is less subjective than IHC interpretation and associated with a greater predictive value of response to HER2-directed therapies. Breast cancer (BC) remains the most common type of cancer in women and the second leading cause of death among women. Chromosome long arm contains an oncoprotein called HER2. The epidermal growth factor receptor (EGFR)/HER1, HER2, HER3, and HER4 are all members of the epidermal growth factor receptor family, which controls cell growth, survival, differentiation, and migration. Extracellular domains of HER2 do not have a known ligand and are activated by homodimers and heterodimers. As a result of these dimers, tyrosine kinase residues in the cytoplasm are phosphorylated, which serve as docking sites for proteins that activate PI3K and MAPK signaling pathways, resulting in cell cycle progression and proliferation. The most common abnormalities of HER2 found in BC are overexpression and amplification, as detected by immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH).
FutureWise Market Research has instantiated a report that provides an intricate analysis of HER2- Positive Breast Cancer Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the HER2- Positive Breast Cancer Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.